Clinical Trials
82 trialsK4CARE-PDAC
Chang Gung Memorial Hospital
HER2 CR
Nagoya City University
SHERLOCK
University Health Network, Toronto
retroESGO ov1
European Society of Gynaecological Oncology
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
University of Aarhus
RT4
The Lymphoma Academic Research Organisation
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Ruijin Hospital
ctDNA in Cutaneous Squamous Cell Carcinoma
Massachusetts Eye and Ear Infirmary
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Peking University People's Hospital
CIRCALL
Assistance Publique - Hôpitaux de Paris
TRACE-BTC
Aarhus University Hospital
GEMINI Breast
Tempus AI
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Peking University People's Hospital
Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
Asan Medical Center
Caris Biorepository Research Protocol
Caris Science, Inc.
EURHOLY
Assistance Publique - Hôpitaux de Paris
Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
Anhui Medical University
NIRVANA
Columbia University
FERTILAM
University Hospital, Lille
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
RenJi Hospital
DUALFLOW
University Hospital, Bordeaux
Clear-HPVca
Massachusetts Eye and Ear Infirmary
FIL_BIOWM
Fondazione Italiana Linfomi - ETS
Risk-adapted Therapeutic Strategy in +1q NDMM
The First Hospital of Jilin University
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
University Hospital, Montpellier
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
University Hospital, Montpellier
NIP IT!
University Health Network, Toronto
LumenDx
JaxBio Ltd
BRALLA
Instituto do Cancer do Estado de São Paulo
Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
Shanghai Zhongshan Hospital
CR1STAL
Second Xiangya Hospital of Central South University
MRD-LUNG
University Medical Center Groningen
MRDSEEKER
National Cancer Center, Japan
B-STRONGER-I
Personalis Inc.
BELUGA
Munich Leukemia Laboratory
MRD-CONFIRM
Assistance Publique - Hôpitaux de Paris
Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery
Second Affiliated Hospital, School of Medicine, Zhejiang University
The clonoSEQ® Watch Registry
Adaptive Biotechnologies
Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
Qingdao Central Hospital
Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
UNC Lineberger Comprehensive Cancer Center
MRD
The First Hospital of Jilin University
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
First Affiliated Hospital of Zhejiang University
Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
Zhujiang Hospital
Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases
Peking University Cancer Hospital & Institute
MARIA
Invitae Corporation
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
University Hospital, Montpellier
SCAN-B
Lund University
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
Jiangsu Cancer Institute & Hospital
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer
First Affiliated Hospital of Zhejiang University